European Society for Biomaterials

Divvy Homes reports: Many Americans Feel They'll Only Ever Own a Home If they Win the Lotto, Inherit Money, or Marry Rich

Retrieved on: 
Friday, June 23, 2023
Housing, Public opinion, Opinion, ESOMAR, Market Research Society, W-2, OnePoll, Marketing, American Association for Public Opinion Research, European Society for Biomaterials, Research, AAPOR, Comparison (grammar), Real estate, Lotto

SAN FRANCISCO, June 23, 2023 /PRNewswire/ -- Home affordability is so out of reach right now that two out of five Americans think they'd need to win the lottery to become homeowners.

Key Points: 
  • Most Americans Feel They'll Only Own a Home If they Win the Lotto, Inherit Money, or Marry Rich
    That's according to a recent survey conducted by OnePoll on behalf of Divvy Homes of 2,000 current non-homeowners.
  • Of respondents, only 53% are confident in any way that they'll be able to own their own home someday.
  • One in five (19%) even said they'd have to marry someone rich.
  • This random double-opt-in survey of 2,000 non-homeowners was commissioned by Divvy Homes between June 5 and June 7, 2023.

Jeff Karp, Ph.D., Joins Eterna’s Scientific Advisory Board

Retrieved on: 
Tuesday, March 28, 2023
Popular Mechanics, Medicine, Society, Broad Institute, Canadian Academy of Engineering, European Society for Biomaterials, Royal Society of Chemistry, Boston Business Journal, Research, Messenger, Biology, Harvard Medical School, MIT Technology Review, National academy, Biomedicine, Patient, ERNA, Outline of health sciences, National Academy of Inventors, Boston (magazine), Hospital, Applied science, BMES, Biomedical Engineering Society, American Institute, Distinguishing, Mechanics, Vaccine, Pharmaceutical industry, Eterna, Engineering, Anesthesia, Brigham

CAMBRIDGE, Mass., March 28, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a life science company committed to realizing the potential of mRNA cell engineering to provide patients with transformational new medicines, today announced the appointment of Jeff Karp, Ph.D. to Eterna’s Scientific Advisory Board.

Key Points: 
  • Matt Angel, Ph.D., Chief Executive Officer and President of Eterna, commented, “Jeff is a world-class expert in drug delivery and cell therapeutics with a successful track record as an entrepreneur whose innovations have spurred numerous biomedical products and companies.
  • Several technologies developed in his lab have led to multiple products currently in development or on the market, and to the launch of ten companies.
  • Most recently, he received the Clemson Award for Applied Research, the highest award for innovation from the Society for Biomaterials.
  • His work has been selected by Popular Mechanics as one of the Top 20 New Biotech Breakthroughs that Will Change Medicine.

Stryker launches Citrefix™ Suture Anchor System, featuring award-winning Citregen biomaterial designed to support bone regeneration and the natural healing process

Retrieved on: 
Tuesday, December 13, 2022
Medical Supplies, Health, Medical Devices, Hospitals, Surgery, Managed Care, Radiology, Society, Chemistry, SYK, European Society for Biomaterials, Patient, Medical and Surgical History of the War of the Rebellion, Spine, NYSE, Surgeon, IHF President's Development Award, Multimedia, Biomaterial, Marketing, Foot, 3D printing, Medical device, Dentistry, Ankle

Stryker (NYSE:SYK) today announced the launch of Citrefix, a suture anchor system for foot and ankle surgical procedures.

Key Points: 
  • Stryker (NYSE:SYK) today announced the launch of Citrefix, a suture anchor system for foot and ankle surgical procedures.
  • View the full release here: https://www.businesswire.com/news/home/20221213005214/en/
    Stryker's new suture anchor system for foot and ankle surgical procedures, featuring the award-winning Citregen, a bioresorbable material designed to mimic the chemistry and structure of native bone.
  • Citrefixs unique suture anchor system is the next step in our expanding Citregen portfolio.
  • Citrefix is a disposable suture anchor system that features a resorbable biomimetic anchor body.

MCRA Expands Recently Formed Biocompatibility Division with 2 Key Hires from FDA and Industry

Retrieved on: 
Tuesday, August 16, 2022
FDA, DC, Nanotechnology, VB, Industry, Senior, SFB, Robotics, CRO, Spine, Growth, Leadership, Quality assurance, SOT, MCRA, LLC, CQA, Knowledge, Communication, Department, Biomedical engineering, Discovery, Toxicology, Society, Neurology, Hotel manager, Google Images, General surgery, European Society for Biomaterials, Associate, RAC, List of life sciences, Safety, VP, Doctor of Philosophy, PMP, Elective surgery, Artificial intelligence, Contract research organization, Regulatory affairs, IVD, PMA, Society of Toxicology, ISO, US Foods, Food, Medical device, Science, Computer security, Biocompatibility

As regulatory scrutiny over device biocompatibility increases, MCRA forms a world class team of biocompatibility experts from FDA and industry.

Key Points: 
  • As regulatory scrutiny over device biocompatibility increases, MCRA forms a world class team of biocompatibility experts from FDA and industry.
  • Key hires Eric M. Sussman, PhD, and Claus Svane Sndergaard, PhD,recently joined MCRA to bring further FDA and industry biocompatibility experience to MCRA's recently established division.
  • Dr. Allen, who leads MCRA's Biocompatibility Team, said "Biocompatibility is a rapidly growing area of need in the medical device industry.
  • The MCRA biocompatibility team is committed to providing clients with biocompatibility advisement that keeps up with these changing technical and regulatory expectations.

The 2022 Society for Biomaterials, Technology Innovation and Development Award goes to Dr. Guillermo Ameer and the Acuitive Technologies Team

Retrieved on: 
Monday, May 9, 2022
Society, Feinberg School of Medicine, Robert R. McCormick School of Engineering and Applied Science, Stent, European Society for Biomaterials, Health, Penn State College of Engineering, Biomedical engineering, Patient, Nanotechnology, Cartilage, Yang, Blood, MIT, Biomedicine, Northwestern University, Skin, Tissue, Publication, Regeneration, Quality of life, Association, Citric acid, Biomaterial, Education, Technology, Research, IFT Research & Development Award, Multimedia, Medical device, Engineering, Northwestern

ALLENDALE, N.J., May 9, 2022 /PRNewswire/ -- It all started with a vision by Northwestern's Dr. Guillermo A. Ameer, Daniel Hale Williams Professor of Biomedical Engineering at the McCormick School of Engineering and Surgery at the Feinberg School of Medicine, who has been awarded the  2022 Technology Innovation and Development Award by the Society for Biomaterials. 

Key Points: 
  • Acuitive Technologies has received 3 FDA Product Clearances for orthopedic devices (Citrelockfixation device, Citrefixsuture anchor and CitrelockACL).
  • The Citrelockfixation device was commercially launched in September 2021 with additional products to be commercialized in Q3 2022.
  • Acuitive also has several innovative Citregenbased products being readied for the market: Citreporesynthetic graft, Citresetsettable biologic adhesive and Citrebridgerotator cuff scaffold.
  • Ameer has co-authored numerous publications in high-impact journals, book chapters, patents, and conference proceedings and has received several awards for his research."